A Fifth Of People With MDS (blood Cancer) Die Prematurely Because The NHS Won't Fund New Life-extending Drugs

The results of a new survey, launched by the UK MDS Patient Support Group, shows that almost a fifth (18 percent) of patients suffering from myelodysplastic syndromes (MDS) - a type of blood cancer - could have lived for longer if they had been able to access treatments that are currently not approved by NICE for treatment on the NHS.